Lion Biotechnologies, Inc. Forecasted to Earn Q3 2017 Earnings of ($0.30) Per Share (NASDAQ:IOVA)

Lion Biotechnologies, Inc. (NASDAQ:IOVA) – Investment analysts at FBR & Co issued their Q3 2017 earnings per share (EPS) estimates for shares of Lion Biotechnologies in a research report issued to clients and investors on Tuesday, according to Zacks Investment Research. FBR & Co analyst M. Kumar anticipates that the biotechnology company will post earnings per share of ($0.30) for the quarter. FBR & Co currently has a “Buy” rating and a $17.50 price target on the stock. FBR & Co also issued estimates for Lion Biotechnologies’ Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($1.22) EPS, Q1 2018 earnings at ($0.34) EPS, Q2 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.36) EPS, FY2020 earnings at ($1.07) EPS and FY2021 earnings at ($0.34) EPS.

A number of other equities research analysts have also weighed in on IOVA. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Lion Biotechnologies in a report on Wednesday, September 13th. Jefferies Group LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Lion Biotechnologies in a research note on Tuesday, September 5th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $13.00 price objective on shares of Lion Biotechnologies in a research note on Tuesday, September 26th. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Lion Biotechnologies in a report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $14.53.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/11/11/lion-biotechnologies-inc-expected-to-earn-q3-2017-earnings-of-0-30-per-share-iova.html.

Lion Biotechnologies (NASDAQ:IOVA) traded up $0.20 during mid-day trading on Friday, hitting $8.05. 517,300 shares of the stock were exchanged, compared to its average volume of 363,658. Lion Biotechnologies has a one year low of $4.45 and a one year high of $8.60.

Lion Biotechnologies (NASDAQ:IOVA) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01).

Several institutional investors have recently bought and sold shares of IOVA. Franklin Resources Inc. purchased a new stake in shares of Lion Biotechnologies during the 2nd quarter valued at $37,844,000. FMR LLC purchased a new position in Lion Biotechnologies in the 2nd quarter worth $20,833,000. Victory Capital Management Inc. purchased a new position in Lion Biotechnologies in the 2nd quarter worth $19,013,000. Broadfin Capital LLC purchased a new position in Lion Biotechnologies in the 2nd quarter worth $16,731,000. Finally, Vanguard Group Inc. purchased a new position in Lion Biotechnologies in the 2nd quarter worth $16,113,000. Hedge funds and other institutional investors own 66.64% of the company’s stock.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Get a free copy of the Zacks research report on Lion Biotechnologies (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply